Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gore

Showing results (181-190 of 314) with videos related to

Pageof 32
Sort By:
Journal of Pharmaceutical Sciences|April 1, 1984
Isolation and identification of piperacillin amide as an impurity in piperacillinM M Siegel, R Mills, L Gehrlein, et al.
Journal of Telemedicine and Telecare|June 26, 1998
Patient satisfaction with realtime teledermatology in Northern IrelandM A Loane, S E Bloomer, R Corbett, et al.
Critical Care Medicine|May 1, 1993
Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusionW J Fawcett, S Hill, J Sheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancerI E Smith, B D Evans, M E Gore, et al.
Journal of Telemedicine and Telecare|September 23, 1998
Diagnostic accuracy and clinical management by realtime teledermatology. Results from the Northern Ireland arms of the UK Multicentre Teledermatology TrialM A Loane, R Corbett, S E Bloomer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 24, 2007
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancerS Bishara, M Griffin, A Cargill, et al.
Clinical and Experimental Immunology|August 1, 1996
IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL)D De Wit, C L Flemming, J D Harris, et al.
BJU International|December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b studyMartin E Gore, Robert J Jones, Alain Ravaud, et al.
British Journal of Cancer|October 11, 2001
The treatment of advanced renal cell cancer with high-dose oral thalidomideJ Stebbing, C Benson, T Eisen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
A phase II trial of ZD0473 in platinum-pretreated ovarian cancerM E Gore, R J Atkinson, H Thomas, et al.
Pageof 32

Showing results (181-190 of 314) with videos related to

Sort By:
Pageof 32
Journal of Pharmaceutical Sciences|April 1, 1984
Isolation and identification of piperacillin amide as an impurity in piperacillinM M Siegel, R Mills, L Gehrlein, et al.
Journal of Telemedicine and Telecare|June 26, 1998
Patient satisfaction with realtime teledermatology in Northern IrelandM A Loane, S E Bloomer, R Corbett, et al.
Critical Care Medicine|May 1, 1993
Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusionW J Fawcett, S Hill, J Sheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancerI E Smith, B D Evans, M E Gore, et al.
Journal of Telemedicine and Telecare|September 23, 1998
Diagnostic accuracy and clinical management by realtime teledermatology. Results from the Northern Ireland arms of the UK Multicentre Teledermatology TrialM A Loane, R Corbett, S E Bloomer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 24, 2007
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancerS Bishara, M Griffin, A Cargill, et al.
Clinical and Experimental Immunology|August 1, 1996
IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL)D De Wit, C L Flemming, J D Harris, et al.
BJU International|December 17, 2016
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b studyMartin E Gore, Robert J Jones, Alain Ravaud, et al.
British Journal of Cancer|October 11, 2001
The treatment of advanced renal cell cancer with high-dose oral thalidomideJ Stebbing, C Benson, T Eisen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
A phase II trial of ZD0473 in platinum-pretreated ovarian cancerM E Gore, R J Atkinson, H Thomas, et al.
Pageof 32